文献速递妇科生殖医学

非典型增生与子宫内膜1级癌孕激素治疗的肿瘤学与生育结局:一项专门肿瘤生育项目的 结果

Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
PubMed 文献 · Gynecol Oncol · 2025-06-30

该研究回顾了2019至2024年转诊至专门肿瘤生育项目的206例患者,其中119例为非典型增生(AH),87例为子宫内膜癌(EC)。170例符合孕激素治疗条件,完全缓解(CR)率为69%(AH 74%;EC 60%),CR后24个月复发概率为32.8%。64例尝试妊娠,36例(56%)受孕,22例(34%;22/64)活产。

要点

  • 在专门肿瘤生育项目中,孕激素治疗的完全缓解率为69%,AH组74%高于EC组60%。
  • 全队列24个月完全缓解概率为86.6%,AH组91.6%显著高于EC组78.4%(p=0.02)。
  • 完全缓解后24个月复发概率为32.8%,AH与EC组间无显著差异(36% vs 27%,p=0.28)。

核心结论

  • 在专门肿瘤生育项目中,患者完全缓解率高且持续至24个月,提示较长治疗期可行。

研究设计与样本

  • 回顾性分析2019至2024年转诊至专门肿瘤生育项目的患者。
  • 该项目提供整合的肿瘤学与生殖内分泌和不孕症(REI)诊疗,遵循标准化治疗路径。
  • 纳入标准:AH/EC 1级组织学、p53野生型状态、无肌层浸润或宫外疾病、有保留生育意愿。
  • 孕激素宫内节育器为主要治疗方式。
  • 初始就诊206例,其中AH 119例(58%),EC 87例(42%);170例符合孕激素治疗条件。

主要发现

  • 完全缓解率69%(AH 74%;EC 60%)。
  • 完全缓解中位时间8.3个月(AH 7.4个月;EC 10.4个月)。
  • 全队列24个月完全缓解概率86.6%(95%CI 77.4-92.0)。
  • AH组24个月完全缓解概率91.6%(95%CI 79.4-96.6)vs EC组78.4%(95%CI 59.8-88.4),p=0.02。
  • 完全缓解后24个月复发概率32.8%(95%CI 20.0-43.6),AH与EC无显著差异(36% vs 27%,p=0.28)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study describes the oncological and fertility outcomes of patients with atypical hyperplasia (AH) or low-grade endometrial cancer (EC) desiring fertility preservation, enrolled in a specialized oncofertility program. METHODS: Patients referred between 2019 and 2024 were reviewed. This novel program provides integrated oncologic and reproductive endocrinology and infertility (REI) care, following standardized treatment pathways. Enrollment criteria include: AH/EC grade 1 histology, p53 wild-type status, no myometrial invasion or extra-uterine disease, and desire to preserve fertility. Progestin intrauterine device was the main mode of treatment. RESULTS: Of 206 patients initially seen, 119 (58 %) had AH and 87 (42 %) had EC. 170 patients were eligible for progestin treatment. Complete response (CR) rate was 69 % (AH 74 %; EC 60 %). The median time to CR was 8.3 months (AH 7.4; EC 10.4). The probability of CR for the whole cohort at 24 months was 86.6 % (95 %CI, 77.4-92.0). The AH group had a significantly higher probability of CR compared to the EC group, 91.6 % (95 %CI, 79.4-96.6) vs 78.4 % (95 %CI 59.8-88.4); p = 0.02, respectively. Despite continuous endometrial protection with progestin, recurrence probability at 24 months after CR was 32.8 % (95 %CI, 20.0-43.6), with no significant difference between AH and EC (36 % vs 27 %, p = 0.28). Sixty-four patients attempted to conceive, and majority underwent assisted reproductive treatment (98 %). Overall, 36 (56 %) patients conceived and 22 of these pregnancies resulted in a live birth (34 %; 22/64). CONCLUSION: Patients in a specialized oncofertility program had high rates of CR that continued up to 24 months suggesting that longer periods of treatment are feasible.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dzyubak O, Glass K, Watts M, et al. Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program. Gynecol Oncol. 2025. PMID: 40592024. doi:10.1016/j.ygyno.2025.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。